Phase Transition Ligands for Cell Surface Receptor Clustering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing multivalent ligands for cell surface molecules face limitations in specificity, selectivity, and systemic toxicity, and lack phase transition adjusting functions to enhance receptor druggability and signaling.
Innovation Solution
A multivalent phase transition adjusting element is developed by covalently linking a multivalent phase transition domain to ligands that can bind specifically to cell surface molecules, enhancing aggregation and signaling without valency dependence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If multivalent ligands are used to induce receptor aggregation, then receptor oligomerization is enhanced, but the enhancement effect is strictly limited by the valency of the ligands
Solution Approach 1:
The patent utilizes liquid-liquid phase separation (LLPS) to enable receptors to form dense liquid condensates on the cell surface. By incorporating phase transition domains (such as FG repeats, IDRs, or low-complexity domains) into the ligand structure, the system triggers a phase transition that concentrates receptors into droplet-like condensates, dramatically enhancing aggregation beyond what traditional multivalent ligands can achieve. This phase transition mechanism allows the system to overcome valency limitations by creating a physical state change that drives massive receptor concentration.
Solution Approach 2:
The patent creates composite ligand structures that combine multiple functional domains: (1) ligand domains for specific receptor binding, (2) phase transition domains (FG repeats, IDRs, LC domains) that drive LLPS, and (3) multivalent scaffolds (such as multimeric proteins or nanoparticle carriers). This composite design integrates specific binding capability with phase separation driving force, enabling both high specificity and enhanced aggregation that overcomes traditional valency constraints.
2Strength
If natural multivalent antibodies are used to increase receptor oligomerization, then aggregation is enhanced, but systemic toxicity risk increases due to inability to recognize multiple targets
Solution Approach 1:
The patent applies local quality by creating ligands with different functional regions having distinct properties: (1) ligand binding domains that provide target-specific recognition, (2) phase transition domains that create local dense condensates at the target site, and (3) multivalent scaffolds that enable cross-linking. This spatial differentiation of functions allows the system to achieve strong local aggregation effects while maintaining overall specificity, reducing off-target effects and systemic toxicity compared to uniform multivalent antibodies.
Solution Approach 2:
The patent segments the ligand into modular functional domains that can be independently designed and optimized: (1) target-specific binding modules, (2) phase transition driving modules (FG repeats, IDRs), and (3) multivalent structural modules. This segmentation allows the system to achieve multivalent binding and phase separation while maintaining flexibility in target selection, enabling recognition of multiple different targets through different binding module combinations, thereby reducing systemic toxicity.
3Strength
If multivalent phase transition domains are used to drive liquid-liquid phase separation, then cell surface molecular aggregation is significantly enhanced, but the complexity of the ligand structure increases
Solution Approach 1:
The patent utilizes parameter changes by incorporating intrinsically disordered regions (IDRs) and low-complexity domains that can change their conformational state in response to binding events. These domains transition from extended, flexible states to condensed, ordered states within the phase-separated condensates. This parameter change (from disordered to ordered) drives the phase separation process and enhances aggregation without requiring complex structured domains, achieving strong aggregation effects through conformational transitions rather than structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The element improves target specificity and selectivity, significantly enhancing cell surface molecular aggregation and signaling, offering refined targeting and regulatory control.
Implementation Method 1
multivalent macromolecules can aggregate due to intermolecular or intramolecular interactions, thereby separating from the common solution phase surrounding the molecules to form an independent liquid phase enriched with the macromolecules. This process is called 'liquid-liquid phase separation (LLPS, also referred to as 'phase separation' herein) or 'phase transition'.
Data Source
AI summary
Provided is a novel phase transition adjusting element, a part of which comprises a multivalent phase transition domain, and the remaining comprises at least two ligands, wherein at least one ligand is covalently connected to the part containing the multivalent phase transition structural domain, the remaining ligands are covalently linked to the part comprising the multivalent phase transition structural domain or to other ligands, and each of the at least two ligands can specifically bind to cell surface molecules corresponding thereto. After binding to cell surface molecules, the phase transition adjusting element can effectively enrich cell surface molecules by means of driving phase separation, and enhance the aggregation of cell surface molecules (such as receptor oligomerization), thereby regulating and controlling various cell physiological and biochemical activities, such as receptor downstream signal transmission, cell endocytosis, etc.